Protein Portal: Enzyme acts as door for the SARS virus

A year ago, a mystery virus began to kill people in China. Causing an illness dubbed severe acute respiratory syndrome (SARS), the virus quickly spread beyond Asia and for a few months stirred fears of a worldwide epidemic.

With stunning speed, scientists identified the virus and decoded its genetic sequence (SN: 4/26/03, p. 262: Out of China: SARS virus’ genome hints at independent evolution). Now, a research team has claimed victory in the race to identify the cellular receptor–the protein to which the virus attaches when it infects cells–for the SARS virus. Since the protein turned out to be a well-known one that had previously been implicated in heart disease, drugs that target the receptor are already under development. Some of those same compounds might serve as antiviral medications for SARS patients, say researchers.

Michael Farzan of Brigham and Women’s Hospital in Boston and his colleagues went fishing for the receptor with a lure made of the molecule on the surface of the SARS virus that docks with the cell’s receptor. They burst monkey-kidney cells, which the virus easily infects, and then cast the viral-surface molecule into the resulting debris.

The SARS-receptor molecule latched on to three proteins, but only one of these, angiotensin-converting enzyme 2 (ACE2), is typically found on the surface of mammalian cells.

Several subsequent experiments, reported in the Nov. 27 Nature, make the case that the human form of ACE2 is a SARS-virus receptor. First, human-kidney cells engineered to produce ACE2 fuse with cells engineered to make the SARS virus’ surface molecule. Second, cells engineered to mass-produce ACE2 were more readily infected by the SARS virus than were normal cells. Third, an antibody to ACE2 slowed the replication of the virus in cells bearing the enzyme.

“We nailed it. It’s lock-solid” that ACE2 is a receptor for the SARS virus, says Farzan.

Another virologist trying to identify the receptor agrees. The results are “very convincing,” says Dimiter S. Dimtrov of the National Cancer Institute in Frederick, Md. “It’s absolutely amazing how quickly they did this.”

Until now, ACE2 has largely interested cardiologists. Several decades ago, physicians began using inhibitors of a similar enzyme, ACE, to treat high blood pressure and heart disease. A few years ago, scientists discovered ACE2 and began to look for compounds that block its activities. There’s a good correspondence between tissues that make ACE2–the heart, lungs, and kidneys, for example–and ones affected by the SARS virus, notes Farzan.

He and his colleagues are now looking into whether known ACE2 inhibitors block the SARS virus from cells. It’s possible that these inhibitors may thwart ACE2’s function but still allow the virus to grab onto the enzyme, cautions Farzan.

Gary Nabel, director of the National Institutes of Health Vaccine Research Center in Bethesda, Md., calls the new work a “fascinating discovery” but notes that the SARS virus may exploit proteins other than ACE2 as receptors.


If you have a comment on this article that you would like considered for publication in Science News, send it to Please include your name and location.

To subscribe to Science News (print), go to

To sign up for the free weekly e-LETTER from Science News, go to

From the Nature Index

Paid Content